基于DOTATATE的α/β放射性核素治疗神经内分泌肿瘤的研究进展  

Progress of studies on DOTATATE-based α/β radionuclide therapy for neuroendocrine neoplasm

作　　者：黄德龙 吴俊豪 何雨航 韩远航 张春波 杨邱亚 Huang Delong;Wu Junhao;He Yuhang;Han Yuanhang;Zhang Chunbo;Yang Qiuya(School of Clinical Medicine,Southwest Medical University,Luzhou 646000,China;Department of Nuclear Medicine,the Affiliated Hospital of Southwest Medical University,Nuclear Medicine and Molecular Imaging Key Laboratory of Sichuan Province,Academician(Expert)Workstation of Sichuan Province,Luzhou 646000,China)

机构地区：[1]西南医科大学临床医学院,泸州646000 [2]西南医科大学附属医院核医学科、核医学与分子影像学四川省重点实验室、四川省院士(专家)工作站,泸州646000

出　　处：《中华核医学与分子影像杂志》2023年第10期627-630,共4页Chinese Journal of Nuclear Medicine and Molecular Imaging

摘　　要：神经内分泌肿瘤(NEN)是1种起源于肽能神经元和神经内分泌细胞的异质性肿瘤。NEN的肿瘤细胞表面存在过表达的生长抑素受体(SSTR)。给予放射性标记的生长抑素类似物(SSA),通过其与过表达SSTR结合进行治疗的方法,为肽受体放射性核素疗法(PRRT)。基于1,4,7,10-四氮杂环十二烷-1,4,7,10-四乙酸- D-苯丙氨酸1-酪氨酸3-苏氨酸8-奥曲肽(DOTATATE)的α/β放射性核素治疗就是PRRT中具有代表性的1种治疗方法。该文主要介绍基于DOTATATE的α/β放射性核素治疗及其相关联合治疗、药物的毒性与安全性的研究进展,展望对NEN治疗具有临床价值的方式。Neuroendocrine neoplasm(NEN)is a type of heterogeneous tumor that originates from peptidergic neurons and neuroendocrine cells.The presence of over-expressed somatostatin receptors(SSTR)on the surface of NEN tumor cells has led to the administration of radiolabeled somatostatin analogs(SSA)in combination with over-expressed SSTR,which is called peptide receptor radionuclide therapy(PRRT).The 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacceticacid-D-Phe1-Tyr3-Thr8-octreotide(DOTATATE)-based α/β radionuclide therapy is one of the representative therapeutic methods of PRRT.This article reviews the progress of research onα/βradionuclide therapy based on DOTATATE and its related combination therapy,drug toxicity and safety,as well as expectation for modalities with clinical value for NEN treatment.

关 键 词：神经内分泌瘤 放射性同位素 Α粒子 Β粒子 发展趋势 

分 类 号：R739.4[医药卫生—肿瘤]